MARKET

PPBT

PPBT

Purple Biotech Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.210
-0.220
-6.41%
After Hours: 3.250 +0.04 +1.25% 19:18 01/21 EST
OPEN
3.400
PREV CLOSE
3.430
HIGH
3.400
LOW
3.120
VOLUME
275.72K
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
3.120
MARKET CAP
57.14M
P/E (TTM)
-0.0659
1D
5D
1M
3M
1Y
5Y
Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors
REHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug...
GlobeNewswire · 01/06 12:30
Is Solid State plc's(LON:SOLI) Recent Stock Performance Tethered To Its Strong Fundamentals?
Solid State (LON:SOLI) has had a great run on the share market with its stock up by a significant 25% over the last...
Simply Wall St. · 01/06 12:24
Is Now An Opportune Moment To Examine Solid State plc (LON:SOLI)?
While Solid State plc ( LON:SOLI ) might not be the most widely known stock at the moment, it received a lot of...
Simply Wall St. · 12/09/2021 08:30
Purple Biotech Announces Initiation Of Part 2 Of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 For Treatment Of Multiple Cancers Supporting Potential Expansion Of Clinical Program
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the initiation of Part 2 of
Benzinga · 12/06/2021 12:33
Purple Biotech Earlier Highlighted Publication In 'Nature Cancer' That Showed Underlying Mechanism Of therapeutic Resistance Of Cancer Cells, Role Of Insulin Pathway On Epithelial Growth Factor Receptor Therapy
Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy NT219, which Targets IRS, Shown to be Highly Synergistic with
Benzinga · 10/22/2021 10:41
We Think Solid State (LON:SOLI) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 09/24/2021 11:38
BRIEF-Purple Biotech To Present Overview Of Ongoing Trial Of Multiple Advanced Cancers Treatment
reuters.com · 09/13/2021 12:51
Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update
One Advanced Pancreatic Cancer Patient Demonstrated a Partial Response in First Dose Cohort in Combination with Nivolumab Patient Enrollment in Second Dose Cohort Complete Study Expanding to Additional Sites in U.S. and Israel REHOVOT, Israel, Sept. 13, 20...
GlobeNewswire · 09/13/2021 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PPBT. Analyze the recent business situations of Purple Biotech Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PPBT stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
High25.00
Average25.00
Low25.00
Current 3.210
EPS
Actual
Estimate
-31.02-23.26-15.51-7.75
Q3 2015
Q4 2015
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 31
Institutional Holdings: 1.17M
% Owned: 6.56%
Shares Outstanding: 17.80M
TypeInstitutionsShares
Increased
1
4.60K
New
3
758.75K
Decreased
3
277.22K
Sold Out
5
98.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/Director
John Waymack
Chief Executive Officer/Director
Itzhak Israel
Chief Financial Officer/Director
Simcha Rock
Vice President - Business Development
Gil Ben-Menachem
General Counsel/Secretary
Avraham Ben-Tzvi
Other
Yisrael Gewirtz
Other
Hadas Reuveni
Independent Director
Ido Agmon
Independent Director
Steven Steinberg
Non-Executive Director
Alain Zeitoun
Independent Director
Philip Serlin
Independent Director
Revital Stern-Raff
Independent Director
Ran Tzror
Independent Director
Arie Weber
No Data
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Webull offers kinds of Purple Biotech Ltd stock information, including NASDAQ:PPBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PPBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PPBT stock methods without spending real money on the virtual paper trading platform.